These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19936010)

  • 1. [Acute renal failure associated with Pemetrexed (Alimta)].
    Porta JM; Vicente de Vera Floristán C; Inglán PB; Jericó JF
    Nefrologia; 2009; 29(6):610-1. PubMed ID: 19936010
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature.
    Brandes JC; Grossman SA; Ahmad H
    Cancer Invest; 2006; 24(3):283-7. PubMed ID: 16809156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed-associated radiation recall dermatitis.
    Khanfir K; Anchisi S
    Acta Oncol; 2008; 47(8):1607-8. PubMed ID: 18607836
    [No Abstract]   [Full Text] [Related]  

  • 4. Pemetrexed (Alimta) for mesothelioma.
    Med Lett Drugs Ther; 2004 Apr; 46(1180):31-2. PubMed ID: 15079145
    [No Abstract]   [Full Text] [Related]  

  • 5. Pemetrexed (Alimta): a novel multitargeted antifolate agent.
    Adjei AA
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):145-56. PubMed ID: 12722874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA drug approval summaries: pemetrexed (Alimta).
    Hazarika M; White RM; Johnson JR; Pazdur R
    Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asteatotic eczema ('eczema craquelé') with histopathological interface dermatitis: a new cutaneous reaction following pemetrexed.
    Frouin E; Sebille G; Freudenberger S; Menecier B; Quoix E; Cribier B; Lipsker D
    Br J Dermatol; 2012 Jun; 166(6):1359-60. PubMed ID: 22182200
    [No Abstract]   [Full Text] [Related]  

  • 9. Pemetrexed-associated urticarial vasculitis.
    Lopes G; Vincek V; Raez LE
    Lung Cancer; 2006 Feb; 51(2):247-9. PubMed ID: 16360237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acute myocardial infarction and pemetrexed].
    Pío-Asín M; Segrelles-Bellmunt G; Arrondo-Velasco A; Sarobe-Carricas M
    Farm Hosp; 2009; 33(2):114-5. PubMed ID: 19480802
    [No Abstract]   [Full Text] [Related]  

  • 11. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
    Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
    Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
    Bracke A; Van Marck E; Lambert J
    Clin Exp Dermatol; 2009 Apr; 34(3):337-9. PubMed ID: 18699838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.
    Mita AC; Sweeney CJ; Baker SD; Goetz A; Hammond LA; Patnaik A; Tolcher AW; Villalona-Calero M; Sandler A; Chaudhuri T; Molpus K; Latz JE; Simms L; Chaudhary AK; Johnson RD; Rowinsky EK; Takimoto CH
    J Clin Oncol; 2006 Feb; 24(4):552-62. PubMed ID: 16391300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis.
    Barlési F; Tummino C; Tasei AM; Astoul P
    Lung Cancer; 2006 Dec; 54(3):423-5. PubMed ID: 17049669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours.
    Nakagawa K; Kudoh S; Matsui K; Negoro S; Yamamoto N; Latz JE; Adachi S; Fukuoka M
    Br J Cancer; 2006 Sep; 95(6):677-82. PubMed ID: 16940981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
    Nambu Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):284-6. PubMed ID: 17301544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
    Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
    Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pemetrexed (Alimta). Laboratory: Lilly].
    Moreno Alvarez PJ
    Farm Hosp; 2004; 28(5):387-8. PubMed ID: 15504098
    [No Abstract]   [Full Text] [Related]  

  • 19. Review of a promising new agent--pemetrexed disodium.
    Paz-Ares L; Bezares S; Tabernero JM; Castellanos D; Cortes-Funes H
    Cancer; 2003 Apr; 97(8 Suppl):2056-63. PubMed ID: 12673697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy.
    Villela LR; Stanford BL; Shah SR
    Pharmacotherapy; 2006 May; 26(5):641-54. PubMed ID: 16637794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.